Evidence map›Paper›PMID 38072497›Full record

ArticleBMJ open2023

Study protocol for a prospective, multicentre, phase II trial on endoscopic treatment using two fully covered self-expandable metallic stents for benign strictures after hepaticojejunostomy.

Yuki Kawasaki, Susumu Hijioka, Yoshikuni Nagashio, Akihiro Ohba, Yuta Maruki, Kotaro Takeshita, Tetsuro Takasaki, Shin Yagi, Daiki Agarie, Yuya Hagiwara and 9 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Yuki KawasakiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.ORCID 0000-0002-5344-7338
Susumu HijiokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan shijioka@ncc.go.jp.
Yoshikuni NagashioDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Akihiro OhbaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Yuta MarukiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Kotaro TakeshitaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Tetsuro TakasakiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Shin YagiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Daiki AgarieDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Yuya HagiwaraDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Hidenobu HaraDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Kohei OkamotoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Daiki YamashigeDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Souma FukudaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Masaru KuwadaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Shunsuke KondoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Hideki UenoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
National Cancer Center Hospital East · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe current endoscopic treatment for postoperative benign hepaticojejunostomy anastomotic stricture (HJAS) has a high technical success rate and is highly effective in the short term. However, long-term results have shown a high rate of stenosis recurrence, which indicates an insufficient response to treatment. Three prospective studies on fully covered self-expandable metallic stent (FC-SEMS) treatment for benign HJAS used the stenosis resolution rate as the primary endpoint, and no study has yet used the long-term non-stenosis rate (at 12 months) as the primary endpoint. METHODS AND ANALYSIS: We launched the 'saddle-cross study', which will be conducted as a multicentre, prospective intervention of endoscopic treatment using two modified FC-SEMSs (BONASTENT️ M-Intraductal) that have been improved for benign stenosis in patients with benign HJAS, with the long-term non-restenosis rate (at 12 months) as the primary endpoint. This study aims to evaluate the long-term non-restenosis rate (at 12 months) and safety of the saddle-cross technique for benign HJAS. We plan to enrol 50 participants. ETHICS AND DISSEMINATION: This study has been approved by the Certified Review Board of the National Cancer Center, Japan (CRB3180009). The results will be reported at various conferences and published in international peer-reviewed journals.

Indexed as

Self Expandable Metallic StentsClinical Trials, Phase II as TopicConstriction, PathologicHumansMulticenter Studies as TopicProspective StudiesRetrospective StudiesStentsTreatment OutcomeEndoscopyGASTROENTEROLOGYHepatobiliary disease

Identifiers

PMID38072497
PMCPMC10729169
OpenAlexW4389521104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.